The only penny stocks site recommended in Barron's and by Forbes.

Online since 1996, we pick stocks trading at under $5.00 that are listed on the NYSE, NASDAQ, and AMEX.

To learn what this site is really about, we urge you to visit the Overview and Track Record pages. However, before doing so, take a glance at a few of our all-time winners. Of course, these are the subsequent gains reached once they hit our target prices and we closed the positions, but it is fun to ponder. The first price was the initial recommendation, followed by the subsequent high, and the eventual ultimate percentage gain. No doubt, you will recognize most of these companies.

Netegrity
(acquired by IBM)
$2.18 to $73.20 3487%
Inhibitex
(acquired by BristolMyersSquibb)
$2.35 to $24.08 925%
Cellstar $1.44 to $13.50 837%
Iomega $3.25 to $13.90 328%
Nanophase $3.75 to $16.75 347%
Immunomedics $1.44 to $29.12 1922%
Total Renal Care $3.12 to $26.95 741%
Voxware $ .90 to $10.31 1046%
Corvas $3.00 to $23.25 675%
Cytogen $2.12 to $17.50 725%
Verilink $3.00 to $14.62 387%
GeneLabs $2.31 to $10.72 364%

"I cannot thank you enough for your excellent newsletter... I do believe I have found a new hobby (and a well paying one, at that), thanks to you!"

— B.K. (Contractor in Saudi Arabia)

See what our subscribers have to say...

 
New! Join our Forum
(Note: this is separate from the Newsletter)
RIGHT NOW!
IN THE LATE JULY 2017 NEWSLETTER

IMPORTANT! We now have nearly 20 second-time picks in our Current Portfolio, so there are a lot to pick from. Read about "OUR NEW PROVEN CHANNELING STRATEGY!"

LISTEN UP PLEASE! Both of our picks for this issue are CHANNELED picks that worked great the first time around.

THREE ANALYSTS rate this biotech a STRONG BUY/BUY that targets immunotherapies for advanced cancers, such as AML and refractory multiple myeloma; trading near its 52-week low at around $1.05. REMEMBER! This is a CHANNELED pick!

THREE ANALYSTS rate this biotech a STRONG BUY/BUY as it develops therapies for neurology, cardiovascular, GI tract diabetes, and pain, and has collaborations with several major pharmaceuticals; trading near its 52-week low at around $2.65. AND REMEMBER: This is another CHANNELED pick!

"I cannot thank you enough for your excellent newsletter... I do believe I have found a new hobby (and a well paying one, at that), thanks to you!"

— B.K. (Contractor in Saudi Arabia)

See what our subscribers have to say...

Forbes Directory - Best of the Web
Best of the Web
(Small Caps)
Barron's > read
review
As Featured:
*BARRON's
*CNNfn.com
*BusinessWeek Online
*Barron's Electronic Edition
InvestOnlineTrading

Ads From Google

"I cannot thank you enough for your excellent newsletter... I do believe I have found a new hobby (and a well paying one, at that), thanks to you!"

— B.K. (Contractor in Saudi Arabia)

See what our subscribers have to say...


The only penny stocks site recommended in Barron's and by Forbes, we pick stocks trading at under $5.00 that are listed on the NYSE, NASDAQ, and AMEX. Penny stock trading involves substantial risk, so always research every recommendation before trading, consult with licensed professionals before trading, and always trade with caution. The recommendations listed in the Newsletter are only for investment ideas and are not solicitations to purchase equities. For more extensive details, view the Privacy Policy and Disclaimer page.
Ads From Google